Bookmark and Share
Ethanol (CID 702) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(6)
 
 
Inactive(238)
 
 
Inconclusive(14)
 
 
Unspecified(1618)
 
 
Top Targets:
7TM GPCR Srx(17)
 
 
7TM GPCR Srsx(15)
 
 
p450(13)
 
 
 
NR LBD PPAR(13)
 
 
 
NR LBD ER(11)
 
 
 
BioAssay Types:
Confirmatory(212)
 
 
 
Literature(78)
 
 
 
 
 
Summary(24)
 
 
BioActivity Types:
Potency(193)
 
 
 
IC50(116)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 1865    Data Row: 1876   Total Pages: 38   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID48413739]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results [AID1205, Type: other]
View
2
[SID48413739]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results [AID1208, Type: other]
View
3
[SID48414916]
DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity [AID1188, Type: other]
View
4
[SID48415981]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
5
[SID103176346]
Compound tested for blood AcH levels in naive rat was determined [AID169653, Type: Literature]
View
6
[SID48413739]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results [AID1189, Type: other]
View
7
[SID103176346]
LC50 2.39883e+11Toxicity determined using Konemann's Industrial Pollutants Toxicity Test [AID162229, Type: Literature]
View
8
[SID103176346]
Inhibition of Rana pipiens muscle activity. [AID168703, Type: Literature]
View
9
[SID103176346]
Antifungal activity against Candida albicans DAY 185 assessed as inhibition of biofilm formation after 24 hrs by XTT reduction assay [AID531319, Type: Literature]
View
10
[SID103176346]
Antifungal activity against Candida albicans DAY 185 assessed as decrease mature biofilm burden after 24 hrs by XTT reduction assay [AID531320, Type: Literature]
View
11
[SID103176346]
Antifungal activity against Candida albicans K1 assessed as decrease mature biofilm burden after 24 hrs by XTT reduction assay [AID531321, Type: Literature]
View
12
[SID103176346]
Antifungal activity against Candida parapsilosis 5986 assessed as decrease mature biofilm burden after 24 hrs by XTT reduction assay [AID531322, Type: Literature]
View
13
[SID103176346]
Antifungal activity against Candida glabrata 5740 assessed as decrease mature biofilm burden after 24 hrs by XTT reduction assay [AID531323, Type: Literature]
View
14
[SID103176346]
FICI in Candida albicans DAY 185 after 24 hrs in presence of flucanozole [AID531324, Type: Literature]
View
15
[SID103176346]
Antifungal activity against Candida albicans DAY 185 grown as planktonic cells by CLSI method [AID531325, Type: Literature]
View
16
[SID103176346]
Antifungal activity against Candida albicans K1 grown as planktonic cells by CLSI method [AID531326, Type: Literature]
View
17
[SID103176346]
Antifungal activity against Candida parapsilosis 5986 grown as planktonic cells by CLSI method [AID531327, Type: Literature]
View
18
[SID103176346]
Antifungal activity against Candida glabrata 5740 grown as planktonic cells by CLSI method [AID531328, Type: Literature]
View
19
[SID103176346]
Antifungal activity against Candida albicans DAY 185 grown as planktonic cells using 10'6 to 10'7 cells by CLSI method [AID531531, Type: Literature]
View
20
[SID103176346]
Antifungal activity against Candida albicans K1 grown as planktonic cells using 10'6 to 10'7 cells by CLSI method [AID531532, Type: Literature]
View
21
[SID103176346]
Antifungal activity against Candida parapsilosis 5986 grown as planktonic cells using 10'6 to 10'7 cells by CLSI method [AID531533, Type: Literature]
View
22
[SID103176346]
Antifungal activity against Candida glabrata 5740 grown as planktonic cells using 10'6 to 10'7 cells by CLSI method [AID531534, Type: Literature]
View
23
[SID103176346]
Inhibition of bovine tubulin polymerization at 10 uM measured every 30 seconds for 60 mins by spectrophotometry relative to control [AID548640, Type: Literature]
View
24
[SID103176346]
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans [AID588211, Type: Literature]
View
25
[SID103176346]
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents [AID588212, Type: Literature]
View
26
[SID103176346]
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents [AID588213, Type: Literature]
View
27
[SID103176346]
In-vitro air to lung partition coefficients of the compound, logK(lung) (human/rat) [AID603950, Type: Literature]
View
28
[SID103176346]
In-vitro air to blood partition coefficients of the compound, logK(blood) (human/rat) [AID603951, Type: Literature]
View
29
[SID103176346]
In-vitro blood to lung partition coefficients of the compound, logP(lung) (human/rat) [AID603952, Type: Literature]
View
30
[SID103176346]
IC50 DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) [AID625158, Type: other]
View
31
[SID103176346]
DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) [AID625164, Type: other]
View
32
[SID103176346]
IC50 DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625165, Type: other]
View
33
[SID103176346]
IC50 DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) [AID625166, Type: other]
View
34
[SID103176346]
DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) [AID625169, Type: other]
View
35
[SID103176346]
IC50 DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) [AID625170, Type: other]
View
36
[SID103176346]
DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) [AID625189, Type: other]
View
37
[SID103176346]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) [AID625190, Type: other]
View
38
[SID103176346]
IC50 DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) [AID625197, Type: other]
View
39
[SID103176346]
IC50 DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) [AID625210, Type: other]
View
40
[SID103176346]
DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) [AID625211, Type: other]
View
41
[SID103176346]
IC50 DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) [AID625212, Type: other]
View
42
[SID103176346]
IC50 DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) [AID625215, Type: other]
View
43
[SID103176346]
IC50 DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) [AID625216, Type: other]
View
44
[SID103176346]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630) [AID625219, Type: other]
View
45
[SID103176346]
IC50 DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil) [AID625224, Type: other]
View
46
[SID103176346]
IC50 DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) [AID625225, Type: other]
View
47
[SID103176346]
DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha) [AID625230, Type: other]
View
48
[SID103176346]
IC50 DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888)) [AID625234, Type: other]
View
49
[SID103176346]
IC50 DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol) [AID625260, Type: other]
View
50
[SID103176346]
IC50 DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam) [AID625261, Type: other]
View